Boniva (ibandronate sodium) is an oral bisphosphonate drug manufactured by Genentech, Inc., GlaxoSmithKline and Roche that is prescribed for women for the prevention and treatment of postmenopausal osteoporosis. The drug is intended to increase bone mass and reduce the risk of spinal breaks. Boniva has been on the U.S. market since it was approved for sale by the FDA in 2003.
In January 2011, Genentech, Inc., GlaxoSmithKline and Roche modified the Full Prescribing Information for Boniva to include a warning on atypical femoral fractures that may result from use of bisphosphonate drugs. The warning includes a very concerning statement indicating that “atypical femur fractures most commonly occur with minimal or no trauma to the affected area.”
The Full Prescribing Information for Boniva also includes warnings regarding the possible development of osteonecrosis of the jaw from taking bisphosphonates as well as the possible development of upper gastrointestinal irritation from taking these types of drugs.
If you or a loved one have taken a bisphosphonate drug such as Boniva, please contact our firm at 1-800-247-1623 or email@example.com for a free consultation to discuss your legal rights.
Boniva® is a registered trademark of Roche Therapeutics Inc. and is used for informational and product identification purposes only.